|
MX2007014474A
(es)
|
2005-05-17 |
2008-02-07 |
Univ Connecticut |
Composiciones y metodos para inmunomodulacion en un organismo.
|
|
CN101365479B
(zh)
|
2005-12-02 |
2013-06-26 |
纽约大学西奈山医学院 |
呈现非天然表面蛋白的嵌合病毒及其应用
|
|
EP2366787B1
(en)
|
2006-01-13 |
2019-12-11 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
|
|
CN108948177B
(zh)
|
2007-05-11 |
2022-04-22 |
阿尔托生物科学有限公司 |
融合分子与il-15变异体
|
|
EP2173378B1
(en)
|
2007-06-27 |
2014-03-19 |
Admune Therapeutics LLC |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
DK2918607T3
(en)
|
2010-09-21 |
2018-01-08 |
Altor Bioscience Corp |
MULTIMERIC IL-15 SOLUBLE MUSCLE MOLECULES AND PROCEDURES FOR PRODUCING AND USING THEREOF
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
ES2634098T3
(es)
|
2011-01-14 |
2017-09-26 |
The Regents Of The University Of California |
Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
|
|
SI3401402T1
(sl)
*
|
2012-06-08 |
2021-03-31 |
Alkermes Pharma Ireland Limited |
Ligandi modificirani s krožno permutacijo kot agonisti in antagonisti
|
|
CA2888896A1
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
US10048271B2
(en)
*
|
2012-12-11 |
2018-08-14 |
Albert Einstein College Of Medicine, Inc. |
Methods for high throughput receptor:ligand identification
|
|
WO2014158811A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
CA2909576C
(en)
|
2013-04-19 |
2023-07-18 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
|
AU2014265487B2
(en)
|
2013-05-14 |
2020-10-22 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (CAR) T-cells
|
|
DK3444271T3
(da)
|
2013-08-08 |
2022-01-10 |
Cytune Pharma |
Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
|
|
HUE046964T2
(hu)
*
|
2013-08-08 |
2020-04-28 |
Cytune Pharma |
Kombinált gyógyászati készítmény
|
|
CA3191031A1
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
AU2014377106B2
(en)
*
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
CN105263521B
(zh)
*
|
2014-01-15 |
2021-06-29 |
卡德门企业有限公司 |
免疫调节剂
|
|
ES2764471T3
(es)
|
2014-02-14 |
2020-06-03 |
Univ Texas |
Receptores de antígeno quimérico y procedimientos de fabricación
|
|
EP3441084A1
(en)
|
2014-02-27 |
2019-02-13 |
Viralytics Limited |
Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
WO2015164107A1
(en)
|
2014-04-23 |
2015-10-29 |
Emory University |
Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
|
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
EP3160498B1
(en)
*
|
2014-06-30 |
2021-10-06 |
Altor BioScience Corporation |
Il-15-based molecules and methods of use thereof
|
|
WO2016018920A1
(en)
|
2014-07-29 |
2016-02-04 |
Admune Therapeutics Llc |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
CN106459219B
(zh)
|
2014-12-19 |
2019-01-08 |
江苏恒瑞医药股份有限公司 |
白细胞介素15蛋白复合物及其用途
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
CN108990413A
(zh)
*
|
2015-08-12 |
2018-12-11 |
麻省理工学院 |
纳米颗粒的细胞表面偶联
|
|
US20170088597A1
(en)
*
|
2015-09-25 |
2017-03-30 |
Altor Bioscience Corporation |
Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
|
|
US11098100B2
(en)
*
|
2015-10-06 |
2021-08-24 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
US11585805B2
(en)
|
2016-02-19 |
2023-02-21 |
Nantcell, Inc. |
Methods of immunogenic modulation
|
|
CA3019005A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3458092A1
(en)
*
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
KR20220148306A
(ko)
*
|
2016-05-27 |
2022-11-04 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
|
CN109715196A
(zh)
*
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
EP3484284A1
(en)
*
|
2016-07-12 |
2019-05-22 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
EP3515471A4
(en)
*
|
2016-09-23 |
2020-07-01 |
The Regents of The University of California |
SELF-MODIFIED LENTIVIRAL-MODIFIED IRRADIATED WHOLE CELL ANTI-TUMOR VACCINES TO EXPRESS CD80, IL-15 AND THE IL-15 ALPHA RECEPTOR
|
|
MX2019004327A
(es)
*
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
EP3529350A1
(en)
*
|
2016-10-19 |
2019-08-28 |
H. Hoffnabb-La Roche Ag |
Method for producing an immunoconjugate
|
|
SG11201903306SA
(en)
|
2016-10-21 |
2019-05-30 |
Altor Bioscience Corp |
Multimeric il-15-based molecules
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
EP3570869A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
|
CN110785435B
(zh)
*
|
2017-03-06 |
2024-01-23 |
艾尔特生物科技公司 |
与il-12和il-18的基于il-15的融合物
|
|
CA3054955A1
(en)
|
2017-03-15 |
2018-09-20 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
US20200121720A1
(en)
|
2017-06-20 |
2020-04-23 |
Nantkwest, Inc. |
Nk-92 cells and il-15 agonist combination therapy
|
|
CN111247242B
(zh)
|
2017-06-21 |
2024-07-19 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
GB2580228B
(en)
*
|
2017-07-03 |
2022-11-02 |
Torque Therapeutics Inc |
Immunostimulatory fusion molecules and uses thereof
|
|
RU2749342C1
(ru)
|
2017-07-25 |
2021-06-08 |
Цзянсу Хэнжуй Медицин Ко., Лтд. |
Фармацевтическая композиция на основе белкового комплекса il-15 и ее применения
|
|
KR20200090742A
(ko)
|
2017-08-28 |
2020-07-29 |
알토 바이오사이언스 엘엘씨 |
Il-7 및 il-21에의 il-15 기반 융합
|
|
CA3074826A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
CA3078735A1
(en)
|
2017-10-12 |
2019-04-18 |
Icell Gene Therapeutics, Llc |
Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
CN111432838A
(zh)
|
2017-12-01 |
2020-07-17 |
美勒斯公司 |
使用双特异性抗体和il-15进行联合治疗
|
|
WO2019126240A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
US11413050B2
(en)
|
2018-01-05 |
2022-08-16 |
Theragi, LLC |
Surgical clip and deployment system
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP2021512104A
(ja)
|
2018-02-02 |
2021-05-13 |
ノバルティス アーゲー |
癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
MY203509A
(en)
*
|
2018-02-26 |
2024-06-30 |
Synthorx Inc |
Il-15 conjugates and uses thereof
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
CN111867612B
(zh)
|
2018-03-26 |
2024-11-12 |
阿尔托生物科学有限责任公司 |
抗PDL1、IL-15和TGF-β受体组合分子
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
US11267866B2
(en)
|
2018-04-04 |
2022-03-08 |
Nant Holdings Ip, Llc |
Immunoglobulin complex comprising interleukin-15
|
|
CN112105645A
(zh)
|
2018-04-18 |
2020-12-18 |
Xencor股份有限公司 |
Il-15/il-15ra异二聚体fc融合蛋白及其用途
|
|
KR20210003813A
(ko)
*
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
|
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CN111988991B
(zh)
*
|
2018-04-26 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
用于追踪动物种群中的动物的方法和系统
|
|
CN110437339B
(zh)
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
KR20250130696A
(ko)
*
|
2018-06-22 |
2025-09-02 |
큐진 인크. |
신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도
|
|
MX2020013977A
(es)
|
2018-06-22 |
2021-06-15 |
Kite Pharma Inc |
Proteínas quiméricas transmembrana y usos de las mismas.
|
|
KR20210038548A
(ko)
|
2018-06-22 |
2021-04-07 |
큐진 인크. |
사이토카인-기반 생체활성 약물 및 이의 사용 방법
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
JP2021532796A
(ja)
*
|
2018-07-30 |
2021-12-02 |
晋宇 張 |
タンパク質ヘテロ二量体およびその使用
|
|
WO2020037120A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Nantbio, Inc. |
Il7-il15 txm compositions and methods
|
|
EP3837277A4
(en)
|
2018-08-17 |
2022-05-11 |
Icahn School of Medicine at Mount Sinai |
RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
|
|
US12486514B2
(en)
|
2018-08-29 |
2025-12-02 |
National University Of Singapore |
Method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
EP4592314A3
(en)
*
|
2018-08-30 |
2025-11-05 |
ImmunityBio, Inc. |
Single-chain and multi-chain chimeric polypeptides and uses thereof
|
|
CN120535649A
(zh)
|
2018-08-30 |
2025-08-26 |
免疫生物公司 |
单链嵌合多肽和其用途
|
|
JP7397874B2
(ja)
|
2018-08-30 |
2023-12-13 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
多鎖キメラポリペプチドおよびその使用
|
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
|
US11701408B2
(en)
|
2018-10-11 |
2023-07-18 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
MX2021004059A
(es)
|
2018-10-12 |
2021-09-23 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
|
|
KR102897353B1
(ko)
|
2018-10-19 |
2025-12-08 |
리전츠 오브 더 유니버시티 오브 미네소타 |
Nk 관여 분자 및 이의 사용 방법
|
|
TW202028226A
(zh)
|
2018-12-13 |
2020-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
CN114344461A
(zh)
|
2018-12-20 |
2022-04-15 |
美勒斯公司 |
用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
|
|
AU2020206269A1
(en)
|
2019-01-11 |
2021-08-05 |
Memorial Sloan Kettering Cancer Center |
Multimerization of IL-15/IL-15R-alpha-Fc complexes to enhance immunotherapy
|
|
WO2020150364A1
(en)
*
|
2019-01-15 |
2020-07-23 |
Altor Bioscience, Llc |
Human immunodeficiency virus-specific t cell receptors
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020231855A1
(en)
|
2019-05-10 |
2020-11-19 |
Nant Holdings Ip, Llc |
Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
WO2020257639A1
(en)
|
2019-06-21 |
2020-12-24 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
EP3853354A4
(en)
|
2019-07-08 |
2022-04-20 |
ImmunityBio, Inc. |
NK CELLS DERIVED FROM MONONUCLEAR CELLS
|
|
US11364291B1
(en)
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
US20210061871A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified N-810 and Methods Therefor
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021113577A1
(en)
*
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
CA3165514A1
(en)
*
|
2019-12-31 |
2021-07-08 |
Navrogen, Inc. |
Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16
|
|
JP2023509770A
(ja)
|
2020-01-08 |
2023-03-09 |
オブシディアン セラピューティクス， インコーポレイテッド |
転写の調節可能な制御のための組成物及び方法
|
|
WO2021142476A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
EP4097043A4
(en)
*
|
2020-01-31 |
2024-05-22 |
Auragent Bioscience, LLC |
ULTRABRIGHT FLUORESCENT NANOCOMPOSITE STRUCTURES FOR IMPROVED FLUORESCENT BIOASSAYS
|
|
PH12022552029A1
(en)
|
2020-02-05 |
2023-11-20 |
Novartis Ag |
Cho cell expressing il-15 heterodimers
|
|
CA3169231A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
US12187763B2
(en)
|
2020-02-11 |
2025-01-07 |
Immunitybio, Inc. |
Chromatography resin and uses thereof
|
|
EP4103599A1
(en)
|
2020-02-11 |
2022-12-21 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
EP4118109A1
(en)
|
2020-03-11 |
2023-01-18 |
NantCell, Inc. |
Proteinaceous therapeutics
|
|
US20230226202A1
(en)
*
|
2020-03-30 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il15 compositions and methods of use thereof
|
|
AU2021260989A1
(en)
|
2020-04-22 |
2022-11-17 |
Novartis Ag |
Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15)
|
|
AU2021262794A1
(en)
|
2020-04-29 |
2022-11-24 |
Immunitybio, Inc. |
Anti-CD26 proteins and uses thereof
|
|
EP4149534A4
(en)
|
2020-05-12 |
2024-09-04 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021253360A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
US12252525B2
(en)
|
2020-07-31 |
2025-03-18 |
Nantbio, Inc. |
Chimeric T cell receptors, nucleic acids, and methods of making and using the same
|
|
JP2023537475A
(ja)
|
2020-08-03 |
2023-09-01 |
ナントセル，インコーポレーテッド |
Ｉｌ－１５スーパーアゴニストに対する薬物に特異的な薬物動態アッセイ
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
KR20230104866A
(ko)
*
|
2020-09-16 |
2023-07-11 |
베이진 엘티디 |
인터류킨 15 작제물 및 사용 방법
|
|
CA3196844A1
(en)
|
2020-11-25 |
2022-06-02 |
Raphael Rozenfeld |
Tumor-specific cleavable linkers
|
|
EP4251741A1
(en)
|
2020-11-30 |
2023-10-04 |
CRISPR Therapeutics AG |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
AU2021410788A1
(en)
*
|
2020-12-23 |
2023-08-03 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11473060B2
(en)
|
2020-12-30 |
2022-10-18 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into NK cells
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
EP4314073A4
(en)
|
2021-03-24 |
2025-02-19 |
Alkermes, Inc. |
Upar antibodies and fusion proteins with the same
|
|
EP4314033A4
(en)
*
|
2021-03-31 |
2025-04-23 |
Anwita Biosciences, Inc. |
FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
|
|
AU2022264339A1
(en)
|
2021-04-28 |
2023-11-09 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN116375888A
(zh)
*
|
2021-05-08 |
2023-07-04 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
AU2022283438A1
(en)
*
|
2021-05-28 |
2024-01-18 |
Akso Biopharmaceutical, Inc. |
BISPECIFIC FC FUSION PROTEINS WITH sPD-1 AND IL-15
|
|
WO2022260849A1
(en)
|
2021-06-09 |
2022-12-15 |
Nant Holdings Ip, Llc |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
JP2025504475A
(ja)
|
2022-01-22 |
2025-02-12 |
ナントセル，インコーポレーテッド |
Ｃｔｌａ４及びｉｌ－１５の融合分子
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120916753A
(zh)
*
|
2023-03-29 |
2025-11-07 |
星锐医药(苏州)有限公司 |
编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
|
|
CN121240886A
(zh)
*
|
2023-06-06 |
2025-12-30 |
杰科生物医药公司 |
白细胞介素-15融合蛋白及其使用方法
|
|
US12227552B2
(en)
|
2023-07-05 |
2025-02-18 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
TW202509219A
(zh)
|
2023-07-13 |
2025-03-01 |
美商艾歐凡斯生物治療公司 |
編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
|
|
US12473529B2
(en)
|
2023-07-18 |
2025-11-18 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
WO2025076124A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
US20250243279A1
(en)
|
2023-10-17 |
2025-07-31 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
US20250134974A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|
|
WO2026006370A1
(en)
|
2024-06-28 |
2026-01-02 |
Immunitybio, Inc. |
Anti-slamf7 antibodies and therapeutics
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|